The new classification of breast cancers: finding the luminal A

Author(s)

Katia Piton Serra ^[1] ; Susana Ramalho ^[2] ; Renato Torresan ^[3] ; Jose Vassallo ^[4] ; Luis Otávio Zanatta Sarian ^[5] ; Geisilene Russano de Paiva Silva ^[6] ; Sophie Derchain ^[7]

Affiliation

^[1] Universidade Estadual de Campinas – UNICAMP. Faculdade de Ciências Médicas. Departamento de Ginecologia e Obstetrícia - Brasil

^[2] Universidade Estadual de Campinas – UNICAMP. Faculdade de Ciências Médicas. Departmento de Anatomia Patológica - Brasil

^[3] Universidade Estadual de Campinas – UNICAMP. Faculdade de Ciências Médicas. Departamento de Ginecologia e Obstetrícia - Brasil

^[4] Universidade Estadual de Campinas – UNICAMP. Faculdade de Ciências Médicas. Departmento de Anatomia Patológica - Brasil

^[5] Universidade Estadual de Campinas – UNICAMP. Faculdade de Ciências Médicas. Departamento de Ginecologia e Obstetrícia - Brasil

^[6] Universidade Estadual de Campinas – UNICAMP. Faculdade de Ciências Médicas. Departmento de Anatomia Patológica - Brasil

^[7] Universidade Estadual de Campinas – UNICAMP. Faculdade de Ciências Médicas. Departamento de Ginecologia e Obstetrícia - Brasil

• Document type: Journal article
• Source: Revista Brasileira de Ginecologia e Obstetrícia; v. 36, n. 12, p. 575-580, 2014-12-00.

Abstract

PURPOSE:To compare the distributions of patients with clinical-pathological subtypes of luminal B-like breast cancer according to the 2011 and 2013 St. Gallen International Breast Cancer Conference Expert Panel.METHODS:We studied 142 women with breast cancer who were positive to estrogen receptor and had been treated in São Paulo state, southeast Brazil. The expression of the following receptors was assessed by immunohistochemistry: estrogen, progesterone (PR) and Ki-67. The expression of HER-2 was measured by fluorescent in situ hybridization analysis in tissue microarray.RESULTS:There were 29 cases of luminal A breast cancers according to the 2011 St. Gallen International Breast Cancer Conference Expert Panel that were classified as luminal B-like in the 2013 version. Among the 65 luminal B-like breast cancer cases, 29 (45%) were previous luminal A tumors, 15 cases (20%) had a Ki-67 >14% and were at least 20% PR positive and 21 cases (35%) had Ki-67 >14% and more than 20% were PR positive.CONCLUSIONS:The 2013 St. Gallen consensus updated the definition of intrinsic molecular subtypes and increased the number of patients classified as having luminal B-like breast cancer in our series, for whom the use of cytotoxic drugs will probably be proposed with additional treatment cost. (AU)

• FAPESP's process: 09/17097-1 - Expression of COX-2 and p53 on molecular subtypes of breast invasive ductal carcinoma and evaluation of its power as a predictive and prognostic factor
• Grantee: Sophie Françoise Mauricette Derchain
• Support Opportunities: Regular Research Grants